On November 12, 2021 InterVenn Biosciences, the leader in glycoproteomics, reported on a predictive signature capable of identifying non-small cell lung cancer patients that will benefit most from immune checkpoint inhibitors (Press release, InterVenn Biosciences, NOV 12, 2021, View Source [SID1234595480]). This signature was developed using InterVenn’s perspectIV platform which combines high-resolution mass-spectrometry-derived glycoprotein profiling with advanced artificial intelligence and neural-networking-based data processing to newly allow glycoproteomic interrogation at clinical scale, opening up a revolutionary, highly powerful new layer of biomarker opportunities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
An oral presentation today at the Conference for the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) outlined the results of a study whereby pre-treatment blood samples from a cohort of patients treated with first-line pembrolizumab (alone or in combination with chemotherapy) were interrogated using the perspectIV platform. A panel of glycopeptide markers predictive of response was identified. This glycopeptide-based signature stratified the patient cohort into two groups which showed significant differences in median overall survival of 2.8 years vs. 0.8 years, at a hazard ratio of 7.4, (p=0.007).
"These results are an important step in the development of our Dawn assay and were the impetus of our current development and validation activities," said Aldo Carrascoso, CEO and co-founder of InterVenn. "We look forward to sharing the results of our current development and validation efforts in NSCLC and other indications as we proceed to the launch of Dawn in 2022."
To find out more about InterVenn Biosciences or partnership opportunities, visit View Source